$SYNH News
Last published 1y ago
- 1y agoSYNHSyneos Health, LLC - Appeal, AffirmedUS Patent Trial and Appeal Board
- 3y agoSYNHSyneos Health Closes Transaction with Private Investment FirmsGlobeNewswireMORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its
- 3y agoCIVIHAYWSPGISYNHCivitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600PR NewswireNEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW)
- 3y agoSYNHSyneos Health Names Terttu Haring President, Clinical Sites & PatientsGlobeNewswireMORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as
- 3y agoSYNHSyneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health EquityGlobeNewswireMORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand
- 3y agoSYNHSyneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured NotesGlobeNewswireMORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the "Issuer" or the "Company") and Syneos Health, Inc. ("Syneos Health"), announced today that, subject to market conditions and other factors,
- 3y agoSYNHSyneos Health Stockholders Approve Agreement with Private Investment ConsortiumGlobeNewswireMORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the
- 3y agoSYNHClick Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos HealthBusiness Wire● The study marks Click's second active randomized clinical trial testing digital interventions in migraine patients. ● The ReMMiD-C trial will evaluate the efficacy and safety of investigational digital therapeutics
- 3y agoCSE:HUGEHUGESYNHArbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201Business WireFSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of
- 3y agoSYNHSyneos Health Appoints Hillary Bochniak as Chief Human Resources OfficerGlobeNewswireMORRISVILLE, N.C., July 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Hillary Bochniak as Chief
- 3y agoARNCEMBKSPPISYNHMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmGlobeNewswireNEW YORK, July 03, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoSYNHSyneos Health and uMotif Partner to Deliver Patient-centric eClinical PlatformGlobeNewswireMORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with uMotif, a
- 3y agoSYNHDose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol - NCT05896969ClinicalTrials.govTreatment emergent adverse events, Pharmacokinetic Assessment, Pharmacodynamic (PD) effect assessment
- 3y agoSYNHFivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos HealthPR NewswireSupporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with
- 3y agoSYNHSyneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health EquityGlobeNewswireMORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Batisha Anson to the newly
- 3y agoSYNHSyneos Health Leaders Recognized by HBAGlobeNewswireMORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer Sozio, SVP Clinical Operations,
- 3y agoSYNHSyneos Health Leaders Recognized as PM360 2023 ELITE Award RecipientsGlobeNewswireMORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites
- 3y agoOXYBROSRIVNIEP+9Stocks making the biggest moves midday: Roblox, Icahn Enterprises, Rivian, Airbnb and moreCNBCThese are the stocks posting the largest moves midday.
- 3y agoHSKAMGTARUTHSYNHMoore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law FirmGlobeNewswireNEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoSYNHSyneos Health Reports First Quarter 2023 ResultsGlobeNewswireRevenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios:
- 3y agoSYNHSyneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 BillionGlobeNewswireShareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the
- 3y agoSYNHSyneos Health Appoints Michael Bonello as Chief Financial OfficerGlobeNewswireMORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as Chief
- 3y agoSYNHA Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa - NCT05817812ClinicalTrials.govChange from baseline in International Physical Activity Questionnaire (IPAQ) scoring, International Physical Activity Questionnaire (IPAQ) score, Change in mean daily minutes in physical activity, (and 39 more...)
- 3y agoSYNHSyneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023GlobeNewswireMORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on
- 3y agoSYNHAssessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects - NCT05807971ClinicalTrials.govTo evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses in healthy participants., Pharmacokinetic assessment 1, Pharmacokinetic assessment 2, (and 15 more...)
- 3y agoSYNHSyneos Health Wins 2023 ViE AwardGlobeNewswireMORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry
- 3y agoSYNHSyneos Health Names Jeanine O'Kane as Communications PresidentGlobeNewswireMORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O'Kane as President of Syneos Health
- 3y agoSYNHSyneos Health Launches Medical Affairs Digital AmplifierGlobeNewswireMORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital
- 3y agoSYNHSyneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset DevelopmentGlobeNewswireMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker of
- 3y agoSYNHSyneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial ContinuumGlobeNewswireMORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement with
- 3y agoCELZSYNHCreative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201Business WireCELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas in the United States Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the
- 3y agoSYNHSyneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT AdoptionGlobeNewswireMORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized Clinical Trial
- 3y agoSYNHSyneos Health Reports Fourth Quarter and Full Year 2022 ResultsGlobeNewswireRevenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios:
- 3y agoSYNHSyneos Health Schedules Fourth Quarter and Full Year 2022 Earnings Call for Thursday, February 16th, 2023GlobeNewswireMORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial
- 3y agoSYNHSyneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial ResearchGlobeNewswireMORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use
- 3y agoSYNHSyneos Health and Haystack Health Partner to Accelerate Clinical Trials with AIGlobeNewswireMORRISVILLE, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Haystack Health,
- 3y agoCYRXSYNHCryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene TherapiesPR NewswirePartnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn., Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc.
- 3y agoSYNHSyneos Health Announces Partnership with Fosun Pharma USA to Launch SerplulimabGlobeNewswireMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA
- 3y agoSYNHSyneos Health Dealmakers' Intentions Survey Sees "Optimism" for M&A and Licensing Deals in 2023GlobeNewswireMORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13th annual Dealmakers' Intentions Survey.
- 3y agoSYNHSyneos Health Announces Chief Financial Officer TransitionGlobeNewswireMORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective March 31, 2023, Jason Meggs
- 3y agoSYNHSyneos Health to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is
- 3y agoSYNHDouble-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - NCT05668650ClinicalTrials.govAUC (area under the curve), Cmax (maximum serum concentration), Tmax (time for maximum serum concentration), (and 3 more...)
- 3y agoSYNHSyneos Health Extends Partnership with MedableGlobeNewswireMORRISVILLE, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has extended its strategic partnership with
- 3y agoSYNHSyneos Health Releases 2023 Health TrendsGlobeNewswireMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 2023 Health Trends: Personally, Purposely
- 3y agoSYNHStudy to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function - NCT05625347ClinicalTrials.govPeak plasma concentration of ASA (Cmax), Area under the ASA plasma concentration versus time curve (AUC0-inf), Area under the ASA plasma concentration versus time curve (AUC0-t), (and 17 more...)
- 3y agoSYNHStudy to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults. - NCT05625334ClinicalTrials.govSerum thromboxane B2 (TxB2) serum concentration - Area under the effect curve (AUEC) of the % Change from baseline (CFB) in serum TxB2 concentration (TxB2 suppression), Proportion of subjects achieving significant inhibition of platelet aggregation (<550 Aspirin Reaction Units [ARU]), TxB2 serum concentration - AUEC of the % CFB in serum TxB2 concentration (TxB2 suppression), (and 8 more...)
- 3y agoSYNHSyneos Health to Participate in Fireside Chat at the 2022 Evercore ISI HealthCONx ConferenceGlobeNewswireMORRISVILLE, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is
- 4y agoSYNHSyneos Health Reports Third Quarter 2022 ResultsGlobeNewswireRevenue for the third quarter of $1,336.2 million decreased 0.9% on a reported basis and increased 2.2% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios:
- 4y agoSYNHSyneos Health Adds HUB Patient Suite to Deployment Solutions BusinessGlobeNewswireMORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it is introducing a dedicated HUB Patient
- 4y agoSYNHPhil, Inc. Forges Strategic Partnership with Syneos Health to Improve Patient Access to PrescriptionsBusiness WirePhil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos